Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

Improving glycaemic outcomes in uncontrolled high risk type 2 diabetes:

The practicalities of using Suliqua®(insulin glargine 100 units/mL and lixisenatide) – why now?

Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.

This promotional webinar was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast.
Editorial support for this webinar was provided by OmniaMed Communications.

Interactive webinar taking place on

5 May 2021 - 13:00 and 19:00

People with uncontrolled type 2 diabetes, particularly those with an HbA1c ≥75 mmol/mol [9%] on two or more oral anti-diabetic drugs (OADs) including metformin, face significant challenges in their journey to achieving glycaemic control and managing their risk of diabetes-related complications and mortality.

Join us for a live webinar on 5 May 2021 at 13:00 and 19:00 hosted by Ed Jude, Consultant in Diabetes and Endocrinology, Tameside Hospital NHS Foundation Trust and Grace Vanterpool, Nurse Consultant – Diabetes, West London NHS Trust. They will explore the role of Suliqua in addressing the challenges facing people with uncontrolled type 2 diabetes currently on two or more OADs. The practicalities of initiating Suliqua in this patient population will also be discussed. Throughout the webinar you will have the opportunity to submit your questions for a live question and answer session with the speakers immediately after the broadcast.

Live Q&A session with Ed Jude and Grace Vanterpool, ready to answer your burning questions

Practical advice on initiating and monitoring treatment in your high-risk patients with uncontrolled type 2 diabetes

CPD accredited webinar with certificate

An hour-long interactive webinar

taking place on 5 May 2021

13:00 and 19:00

including a 20-minute live Q&A

Agenda

5 minutes

Introduction and welcome

  • Setting the scene:
    • The current state of the nation and the reality facing people with uncontrolled type 2 diabetes
    • NICE recommendations for people with uncontrolled type 2 diabetes with an HbA1c  ≥75 mmol/mol [9%] currently on OADs
  • The rationale for using the fixed ratio combination Suliqua (insulin glargine 100 units/mL and lixisenatide)

Ed Jude

10 minutes

Intensification to premixed insulin:
What are the challenges?

  • Balancing the need to achieve glycaemic control vs. increased risk of weight gain and hypoglycaemia associated with premixed insulin
  • Real-world data illustrating the low probability of achieving glycaemic targets with premixed insulin

Ed Jude

10 minutes

The role of Suliqua in addressing unmet needs

  • Summary of key findings from Phase III trials
  • Comparing Suliqua with other approaches: Results from a recent network meta-analysis

Ed Jude

15 minutes

Initiation of Suliqua in people with uncontrolled type 2 diabetes on OADs: A practical guide

  • Introducing Suliqua and licensed indications
  • Which patients are suited to Suliqua?
  • Initiation and titration of Suliqua
  • Monitoring patients in a virtual setting

Grace Vanterpool

20 minutes

Live Q&A session

Ed Jude and
Grace Vanterpool

Speakers

Ed Jude

Consultant in Diabetes and Endocrinology, Tameside Hospital NHS Foundation Trust

Grace Vanterpool

Nurse Consultant, Diabetes, West London NHS Trust

Improving glycaemic outcomes in uncontrolled
high risk type 2 diabetes:

The practicalities of using Suliqua®(insulin
glargine 100 units/mL and lixisenatide) – why now?

Taking place on 5 May 2021

13:00 and 19:00

Days
Hours
Minutes
Seconds

Prescribing information for Suliqua (insulin glargine 100 units/mL and lixisenatide) can be accessed by clicking here.

This promotional webinar was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Sanofi Tel: 0800 0902314. Alternatively, send via email to UK-drugsafety@sanofi.com

Job code: MAT-GB-2005380 (v1.0) | Date of preparation: March 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.